Background and Aims-Interleukin 10 (IL10) inhibits monocyte/macrophage and T lymphocyte effector functions. This study examined the effect of systemically administered IL10 on acute and chronic granulomatous enterocolitis, hepatitis, and arthritis in a rat model. Methods-Lewis rats were injected intramurally with streptococcal peptidoglycan-polysaccharide (PG-APS) polymers. Beginning 12 hours before PG-APS injection, rats were treated daily with subcutaneous murine recombinant IL10 or vehicle for three or 17 days. Results-IL10 attenuated acute enterocolitis in a dose dependent fashion (p<0.01). Protective effects were more profound in the chronic granulomatous phase with decreased enterocolitis and markedly inhibited leucocytosis, hepatic granulomas, and chronic erosive arthritis (p<0.001). IL10 downregulated tissue IL1, IL6, tumour necrosis factor a, and interferon y gene expression, consistent with the in vitro effects of IL10 on PG-APSstimulated splenocytes. Caecal IL1 protein concentrations and IL2 and interferon -V secretion by in vitro stimulated mesenteric lymph nodes were downregulated in IL10 treated animals. Conclusions-These results indicate that exogenous IL10 can inhibit experimental granulomatous inflammatory responses and suggest that IL10 treatment could be an effective new therapeutic approach in human disorders such as Crohn's disease, rheumatoid arthritis, and sarcoidosis.
Inflammatory processes play a central part in mediating immune host defences to infectious pathogens and in wound healing, but an unrestrained, overly aggressive inflammatory response can induce inappropriate tissue destruction. Recent observations in animal models show that the chronicity of inflammation is determined by a dysregulated balance of pro and anti-inflammatory cytokines. [1] [2] [3] Chronic immune mediated disorders like inflammatory bowel diseases (IBD), rheumatoid arthritis, and type I diabetes mellitus seem to arise from a genetically determined dysregulated immune response to ubiquitous antigens.4`6 Therefore immunomodulatory interventions that utilise endogenous immunosuppressive molecules provide an attractive, relatively non-toxic approach to treating these chronic, idiopathic disorders.
Interleukin 10 (ILIO), originally named cytokine synthesis inhibitor factor, is a cytokine that inhibits many immune effector functions. IL10 is produced by a variety of cells including T lymphocytes, B cells, and macrophages and suppresses the in vitro production of interferon (IFN) y and IL2 by Thi lymphocytes and IL1, IL6, IL8, tumour necrosis factor (TNF) a, granulocyte-macrophage colony stimulating factor, and granulocyte colony stimulating factor by monocytes/macrophages.7 8 Several in vivo findings in experimental animal models suggest that ILl 0 is an important anti-inflammatory agent. Increased IL10 gene expression correlates with recovery in experimental autoimmune encephalomyelitis9 and recombinant IL10 treatment attenuates the clinical course of this disease.'0 Spontaneous intestinal inflammation occurs in IL10 deficient (knockout) mice" and continuous administration of IL10 attenuates experimental colitis in a lymphocyte transfer model.'2 Furthermore, IL10 therapy prevents early death and pancreatic necrosis in models of experimental endotoxaemia'3 and acute pancreatitis14 respectively, probably by down regulating TNFoa. Finally, blockade of endogenous IL10 increases the severity of experimental arthritis in mice."
Peptidoglycan-polysaccharide (PG-PS) polymers, the basic structural component of the cell walls of Gram positive and Gram negative bacteria, induce acute inflammation, which in the susceptible host proceeds into a relapsing, granulomatous inflammatory reaction in several organs.'1'9 The granulomatous enterocolitis model in susceptible Lewis rats is characterised by chronic, transmural, spontaneously relapsing intestinal inflammation, accompanied by hepatic granulomas, erosive arthritis, chronic anaemia, and leucocytosis. '7 Inflammation is induced by subserosal (intramural) injection of PG-PS from group A Streptococcus pyogenes (PG-APS) into the terminal ileum and caecum. Inflammation in this model follows a biphasic course. The acute phase of focal intestinal inflammation peaks one to three days after PG-APS injection, then gradually resolves, but is followed after [10] [11] [12] [13] [14] days by a spontaneous reactivation with extensive granulomatous intestinal and systemic inflammation. ILI is involved in the pathogenesis of acute and chronic phases of this model because caecal ILI concentrations are increased and ILI receptor antagonist (IL1 RA) treatment attenuates inflammation.'7 T lymphocytes are necessary for the chronic granulomatous phase of PG-APS induced inflammation, as cyclosporin A completely prevents chronic inflammation and granuloma formation in the gut, liver and joints, and athymic animals fail to develop chronic inflammation after PG-APS injection.2022
Because T lymphocytes and pro-inflammatory cytokines such as ILI are involved in the pathogenesis of intestinal, liver, and joint inflammation in the PG-APS model, we postulated that ILl 0 therapy should exert a protective effect. In this study we examined the ability of recombinant murine ILl0 to prevent intestinal and systemic inflammation in the PG-APS enterocolitis model and investigated the in vivo and in vitro effects of IL10 on the regulation of key pro-inflammatory cytokines. (5 X 106 cells/ml) were cultured for six hours in the presence of PG-APS (50 ,ug/ml) and IL10 (0, 1, 5, 50 or 250 ng/ml).
Methods

Animals and reagents
The culture medium was RPMI 1640 supplemented with 5% heat inactivated fetal calf serum, 2 mM glutamine, 5 X 10-6 M 2-mercaptoethanol, 100 units/ml penicillin G, 1000 ,ug/ml streptomycin sulphate, and 0. 25 ,ug/ml amphotericin B. Total RNA was isolated using Trizol (Gibco, Grand Island, MY) and stored at -80°C until further processing.
Induction of enterocolitis by PG-APS Lewis rats, randomised into treatment groups, were anaesthetised (20 gil/100 g by intramuscular injection Innovar-Vet; Pitman Moore, Washington Crossing, NJ), and intestines were exposed by laparotomy using aseptic technique. Rats were injected subserosally with PG-APS using a total dose of 12.5 pug/g body weight rhamnose (equivalent to 37.5 ,ig dry wt PG-APS/g body weight) distributed among seven injection sites in the ileal Peyer's patches, terminal ileum, and caecum as previously described. 24 25 Joints were measured before PG-APS injection and serially thereafter. To reduce bias, all groups were coded, and the rats were selected randomly from the cages, so that no identification was visible to the person making the measurements. Data were expressed as the increase of joint diameter in mm compared with the baseline measurement before PG-APS or HSA injection.
Histological and biochemical evaluation of inflammation A histological inflammatory score was evaluated for each animal by a blinded observer as described previously. '7 Briefly, values from 0-4 (4 being the most severe) were assigned for both acute and chronic inflammation in the different layers of the intestine in coded cross sections of the terminal ileum, mid caecum, and caecal tip. The acute and chronic scores of each animal were totalled, a score of 24 representing the maximum possible histological inflammatory score.
Measurement of myeloperoxidase activity Caecal myeloperoxidase (MPO) activity was determined using a modified standard method.26 Briefly, caecal tissue was homogenised in 4 ml 20 mmol/l phosphate buffer (pH 7.4) and centrifuged at 4000 rpm at 4°C for 20 minutes. The pellet was homogenised and sonicated with 2 ml 50 mmoIl acetic acid (pH 6) containing 05% (wt/vol) hexadecyltrimethylammonium hydroxide. MPO RNA preparation Total tissue RNA was prepared using a standard method with guanidine thiocyanatecesium chloride as previously described.'7 Total RNA was quantified by ultraviolet spectrophotometry (A260/A280). The integrity and quality of each RNA sample was checked by electrophoresis on a 1% agarose gel containing ethidium bromide.
Polymerase chain reaction (PCR) For each sample 1 ,ug of total RNA was reverse transcribed in a total volume of 25 gl containing lXfirst strand buffer (Gibco, Grand Island, NY) 125 U of Moloney murine leukaemia virus RT (Gibco, Grand Island, NY), 15 U RNAse inhibitor (Promega, Madison, WI), 0.5 mM each of four dNTPs (Pharmacia, Piscataway, NJ), and 5 pmol of random Hexamers (Pharmacia, Piscataway, NJ). The reaction was carried out at 39°C for one hour, followed by 93°C for seven minutes, 24°C for one minute, and finally cooled down to 4°C for 30 minutes. The reaction mixture was stored at -20°C until further use.
The amplification was carried out in a 9600 Perkin-Elmer cycler (Applied Biosystem, Foster City, CA). One to 2 ,ul of cDNA sample was amplified in 50 ,lI of a reaction mixture containing 1 XTaq buffer II (Perkin Elmer, Norwalk, Co), 1.5 mM MgCl2, 2 pLM each of 5' and 3' primers and 1 U of TAQ polymerase (Perkin Elmer, Norwalk, CO). Samples were heated for four minutes at 94°C and the following cycles were conducted at 94°C for 45 seconds, 60°C for 45 seconds, 72°C for 1.30 minutes. At the end the reaction mix was held at 72°C for five minutes. Negative controls without cDNA were amplified with each PCR experiment. To confirm that equal amounts of RNA were added in each PCR within an experiment and to verify a uniform amplification process P actin mRNA was reverse transcribed and amplified in each assay. Aliquots of the samples were analysed by electrophoresis on a 2% agarose gel containing ethidium bromide. The DNA products were visualised by ultraviolet fluorescence and photographs of the gels were taken with a negative film (Polaroid 665, Polaroid Corp, Cambridge, MA). The negative was scanned with a Silverscanner II PS v2.Aa using Adobe Photoshop 2.5.1 software.
Primers specific for rat cytokines were constructed according to published sequences27~33 and are listed in Table I . The authenticity of the PCR product was confirmed by comparing actual and predicted size using a 100 bp DNA ladder (Gibco) and by observation of fragments of predicted sizes after digestion with the listed restriction enzymes: EcoR I (IFNy), TAQ I (TNFac, ILI RA), BgI II (IL6), Acc I (IL1 at), BamH I (IL>).
Cell cultures of mesenteric lymph nodes (MLN) Mesenteric lymph nodes from rats treated with IL10 or the vehicle were removed, gently minced, and filtered through a fine mesh.
The cells were washed and resuspended (5X 106 in 1 ml) in RPMI and additives as described above. The cells were cultured at 37°C in 5% CO2 and 95% 02 in a 24 well tissue culture plate for 10 or 36 hours in the presence or absence of concanavalin A (1 ,ug/ml), after which the supematants were collected for the assays. Experiments were performed with cells from at least three individual animals.
Cytokine assays ILla: Caecal tissues were homogenised in ice cold 20 mmol/l phosphate buffer (pH 7.4) and the supernatant kept at -80°C until assay. The homogenates were measured in 1:1 dilutions using a radioimmunoassay kit for rat ILlcx (Cytokine Science, Boston, MA).
IFNy activity was measured by a rat IFNy ELISA (Biosource Int; Camarillo, CA). IL2 was measured in a bioassay using the murine cell line designated NK. Briefly, titrated amounts of culture supematants were added to NK cells (5 X 103 cells/well in 100 ,l culture volume) and incubated for 48 hours.
The cultures were pulsed with 3H-thymidine for the last four hours. Cells were harvested and incorporation of 3H-thymidine was determined by scintillation counting. Units per ml of IL2 are defined as the reciprocal of the dilution of supematant that stimulates 50% of the maximal counts per minute of 3H-thymidine incorporation, multiplied by 10 as the bioassay volume is 0 1 ml.
Statistical analysis
Data were analysed using a statistical software (Statview II; Abacus Concept, Berkely, CA).
Differences between the groups were compared using one way analysis of variance or using x2 analysis. Differences 
Results
In vitro inhibition of cytokines by ILIO To demonstrate the potential anti-inflammatory role of recombinant murine IL10 on rat cells stimulated with PG-APS, we isolated splenocytes from Lewis rats and added 50 ,ug/ml PG-APS and different concentrations of ILIO for six hours. PG-APS markedly upregulated IFNy, ILlox, and TNFo gene expression in splenocytes in vitro (Fig 1) . Fifty and 250 ng/ml recombinant murine ILl 0 inhibited gene expression of IFNy, ILlot, and TNFa in a dose dependent fashion (Fig 1) , whereas lower doses (1 or 5 ng/ml) were ineffective (results not shown).
Effects ofILIO treatment on the acute inflammatory phase Two different doses of recombinant murine IL10, 100 or 250 jig/kg, were administered daily by subcutaneous injection, starting 12 hours before surgery. Three days after surgery, the rats were killed and the inflammatory changes of the intestine were scored in a blinded fashion. An amelioration of the gross gut score (GGS) with a significant benefit by the higher IL10 dose (250 ,ug/kg) was observed (Fig 2A) . In the analysis of the different components of the GGS, the most significant improvement was in decreased caecal thickening (mean (SEM)) (1. (Table III) . However, these three IL10 treated animals showed considerably less hepatic inflammation than the PG-APS/RSA animals in regard to histological distribution and destruction of liver parenchyma. Although parenchymal granulomas were only rarely seen in the liver of IL10 treated rats, a mononuclear cell infiltrate was observed around bile ducts (Fig 3) . The increase in liver weight of PG-APS injected/ILl 0 treated rats compared with non-PG-APS injected controls was decreased by 45% (p<0-03) (Table III) Days after PG-APS injection Murine recombinant IL10 treatment suppressed the development of chronic arthritis in a highly significant fashion (Fig 4) . On day 17 after PG-APS injection joints of IL10 treated rats were not significantly increased over HSA/RSA negative controls; the increase in the mean (SEM) joint diameter from preinjection values seen in the PG-APS/RSA group was reduced by nearly 80% (1.85 (0.37) mm in the PG-APS/RSA versus 0.38 (0.19) mm in the PG-APS/IL10 treatment group, p<0-001) (Fig 4) . Only two of 10 animals showed clinical signs of arthritis after IL10 treatment with very attenuated arthritis in one of the two rats, whereas eight of 10 animals in the PG-APS/ RSA group clinically showed profound arthritis with marked swelling and erythema. The histopathology of the joints confirmed the clinical pattern. Figure 5 shows that infiltration of PMNs and mononuclear cells, pannus formation, cartilage erosion, bone degradation as well as exudation of cells into the joint space were clearly inhibited by IL10 treatment. Effects ofILJ O treatment on cytokine regulation IL10 reduced or inhibited the expression of ILla and P, TNFac, IL6, and IFNy genes in the liver, mesenteric lymph nodes, and caecal tissues as measured by RT-PCR. The most pronounced effects were seen in the liver consistent with the marked differences in hepatic granuloma formation (Fig 6) . Expression of IL1 RA and ILIO mRNA (results not shown) did not differ between the IL10 treated and not treated groups; these cytokines were also constitutively expressed in non-inflamed HSA/RSA controls.
Earlier studies showed significantly increased ILlot protein concentrations in caecal tissues in the chronic phase after PG-APS subserosal injection.'7 IL10 treatment decreased ILla protein levels by 40% (Fig 7) . Furthermore, we assessed the production of IFNy and IL2 by concanavalin A stimulated MLN cells, isolated 17 days after PG-APS injection. Whereas MLN cells showed no measurable spontaneous production of IFNy or IL2, concanavalin A stimulation upregulated the production of IFNy twofold and IL2 25-fold in PG-APS/RSA 25r- HSA/RSA (n= 10) (n = 10) (n = 5) 51 In our model in vivo IL10 treatment downregulated IFN-y and IL2 protein secretion of mesenteric lymph nodes after Con A stimulation and inhibited tissue IFNy gene expression. Furthermore in vitro ILIO decreased IFN-y upregulation in PG-APS activated splenocytes. Negative regulation of IFNy by ILIO is the suggested mechanism of disease prevention in the experimental allergic encephalomyelitis model'0 and in the non-obese diabetic mouse model. 52 As shown here, IL10 downregulated expression of several pro-inflammatory cytokines in vivo. However, we cannot determine if these protective effects are direct or indirect through induction of other inhibitory cytokines, like ILI RA, or by inhibition of pro-inflammatory mediators like IL12. IL1 RA, which attenuates PG-APS induced enterocolitis and systemic inflammation,'7 25 is upregulated in the presence of IL10 in LPS activated neutrophils,53 whereas IL10 had no effect on IL1 RA production by mononuclear cells isolated from patients with rheumatoid arthritis54 or in vitro endotoxin stimulated whole blood from healthy volunteers after intravenous ILIO administration. 55 The PG-APS model, which displays genetically determined host susceptibility, ileocaecal inflammation, extraintestinal manifestations of anaemia, leucocytosis, hepatobiliary inflammation, arthritis, and exhibits spontaneous relapses of inflammation, resembles many features of Crohn's disease. Furthermore, PG-APS is an environmentally relevant agent, which is present in high concentrations in the lumen of the distal ileum and colon. Ubiquitous anaerobic bacteria and their cell wall components seem to be involved in IBD and reactive arthritis.'9 60 Our results demonstrate that IL10 down regulates experimental chronic granulomatous inflammation induced by bacterial cell wall components in genetically susceptible hosts. In this model IL10 appears to act by suppressing the expression of monokines and IFNy. Immunomodulating IL10 treatment could be a new effective therapeutic approach for chronic inflammatory diseases in humans, particularly Crohn's disease and rheumatoid arthritis, which are characterised by increased tissue concentrations of products of activated macrophages and Thl lymphocytes.5 44 61 
